Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

Novel Approaches to Study Prevalent Chronic Diseases as Alternatives to Large-Scale Clinical Trials

Session Chair(s)

Max  Wegner, PharmD, RPh

Max Wegner, PharmD, RPh

Head Regulatory Affairs

Bayer AG, Germany

The current paradigm of conducting large-scale clinical trials in highly prevalent and chronic diseases does not support timely access of patients to innovative medicines. We will discuss possible ways to transform drug development in these areas.

Learning Objective : Summarize the patient, regulatory,and industry perspectives on the sustainability of doing large-scale clinical development programs for highly prevalent and chronic diseases and conditions; Name possible alternate and novel approaches to drug development in highly prevalent and chronic disease areas, outside of large-scale clinical trials.

Speaker(s)

James T. Mayne, PhD

Biopharmaceutical Industry Perspective

James T. Mayne, PhD

Pharmaceutical Research and Manufacturers of America (PhRMA), United States

Vice President, Scientific Advocacy

Peter P. Stein, MD

Addressing Reduced Investment in Drug Development for Many Common Chronic Diseases

Peter P. Stein, MD

FDA, United States

Director, Office of New Drugs, CDER

Sue  Peschin, MHS

Novel Approaches to Study Diseases in Older Adults

Sue Peschin, MHS

Alliance for Aging Research, United States

President and Chief Executive Officer

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.